Vicente Sánchez María Pilar, Macías Saint-Gerons Diego, de la Fuente Honrubia César, González Bermejo Diana, Montero Corominas Dolores, Catalá-López Ferrán
División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España.
Rev Esp Salud Publica. 2013 May-Jun;87(3):247-55. doi: 10.4321/S1135-57272013000300004.
For years, anxiolytics and hypnotics have been one of the most prescribed drug classes in most developed countries. The main aim of this study is to explore the pattern of use of anxiolytic and hypnotic drugs during the period 2000-2011, comparing their growth with that of five european countries.
We performed an ecological and descriptive study of anxiolytics and hypnotics consumption in Spain. Consumption data were obtained from the databases of medications dispensed in community pharmacies and charged through official prescriptions to the totality of the Spanish National Health System. Annual and total-period consumptions were expressed in defined daily doses (DDD) per 1000 inhabitants per day (DDD/1000 person/day) by each treatment subgroup, active substance and attending the plasma half-life of the medication. Approximate comparisons were also made with some European countries.
The use of anxiolytics and hypnotics drugs was 56.7 DDD/1000 person/day in 2000 and 82.9 DDD/1000 person/day in 2011 (a +46.1% increase across the period). Lorazepam and alprazolam were the most used anxiolytics (20.5 and 15.6 DDD/1000 person/day in 2011, respectively), whereas lormetazepam was among the hypnotics (18.3 DDD/1000 person/day in 2011). In relative terms, hypnotics´ lormetazepam and zolpidem increased their use by 103.3% and 85.1%, respectively; while anxiolytics´ lorazepam and hydroxyzine increased 75.1% and 72.8%, respectively. In Spain (period 2003-2010), the total increase in the consumption of anxiolytics and hypnotics was +34.3%, with 24.0% for Portugal, 4.0% for Italy, but a reduction of -6.1% for France.
A considerable increase in anxiolytics and hypnotics´ consumption has occurred in Spain during the last decade, being the growth higher than that reported in other European countries.
多年来,在大多数发达国家,抗焦虑药和催眠药一直是处方量最大的药物类别之一。本研究的主要目的是探讨2000年至2011年期间抗焦虑药和催眠药的使用模式,并将其增长情况与五个欧洲国家进行比较。
我们对西班牙抗焦虑药和催眠药的消费情况进行了一项生态学和描述性研究。消费数据来自社区药房配发药物的数据库,并通过官方处方向西班牙国家卫生系统的全体人员收费。每年和整个时期的消费量按每个治疗亚组、活性物质并参照药物的血浆半衰期,以每1000居民每天的限定日剂量(DDD)表示(DDD/1000人/天)。还与一些欧洲国家进行了大致比较。
2000年抗焦虑药和催眠药的使用量为56.7 DDD/1000人/天,2011年为82.9 DDD/1000人/天(在此期间增加了46.1%)。劳拉西泮和阿普唑仑是使用最多的抗焦虑药(2011年分别为20.5和15.6 DDD/1000人/天),而氯美扎酮属于催眠药(2011年为18.3 DDD/1000人/天)。相对而言,催眠药氯美扎酮和唑吡坦的使用量分别增加了103.3%和85.1%;而抗焦虑药劳拉西泮和羟嗪分别增加了75.1%和72.8%。在西班牙(2003年至2010年期间),抗焦虑药和催眠药的消费总量增加了34.3%,葡萄牙为24.0%,意大利为4.0%,但法国减少了6.1%。
在过去十年中,西班牙抗焦虑药和催眠药的消费量大幅增加,其增长高于其他欧洲国家报告的增长水平。